SAGE Open Med. 2016 Oct 25;4:2050312116675813. eCollection 2016.

Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland.

Waqas S¹, O'Connor M², Levey C², Mallon P³, Sheehan G¹, Patel A⁴, Avramovic G⁴, Lambert JS⁵.

Author information

1: Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin, Ireland.
2: Pharmacy Department, Mater Misericordiae University Hospital, Dublin, Ireland.
3: Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin, Ireland; University College Dublin, Dublin, Ireland.
4: Catherine McAuley Education & Research Centre, Mater Misericordiae University Hospital, Dublin, Ireland.
5: Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin, Ireland; University College Dublin, Dublin, Ireland; Rotunda Hospital, Dublin, Ireland.

Abstract

OBJECTIVE:

Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir.

METHODS:

Retrospective health care record of 61 consecutive HIV treatment-naive patients started on dolutegravir was reviewed and analysed on SPSS.

RESULTS:

The mean initial viral load was 160826.05 copies/mL (range, 79-1,126,617 copies/mL). HIV viral load became non-detectable in 63.9% of patients on dolutegravir within 3 months. In all, 60.7% of patients reported no side effects on dolutegravir; 98.4% of the patients claimed full compliance to their antiretrovirals.